Navigation Links
Hagens Berman Sobol Shapiro LLP and Douglas & London P.C. Announce Proposed Class Action Settlement in Bayer Combination Aspirin Products Litigation
Date:9/7/2012

CHICAGO, Sept. 7, 2012 /PRNewswire/ -- The following statement is being issued by Hagens Berman Sobol Shapiro LLP and Douglas & London P.C. pursuant to an order of the United States District Court for the Eastern District of New York:

If you purchased either of the following Bayer Aspirin products in the U.S., you may be entitled to compensation. 

Bayer® Aspirin With Heart Advantage
1/1/08 – 7/23/12

Bayer® Women's Low-Dose Aspirin + Calcium
1/1/00 – 7/23/12

WHAT IS THIS LAWSUIT ABOUT?
Plaintiffs claim that Bayer overcharged consumers for Bayer® Aspirin With Heart Advantage and Bayer® Women's Low-Dose Aspirin + Calcium ("Combination Aspirin Products") or that these products should not have been sold, because these products were not FDA-approved, could not provide all advertised health benefits and were inappropriate for long-term use.  Bayer denies it did anything wrong.  The Court has not decided who is right and who is wrong.  The lawsuit is called In re Bayer Corp. Combination Aspirin Products Marketing & Sales Practices Litigation, No. 09-MD-2023 (BMC) (JMA) in the United States District Court for the Eastern District of New York.

WHAT ARE THE TERMS OF THE SETTLEMENT?
Under the terms of the proposed settlement, each Settlement Class Member who submits a valid claim may be entitled to money.  Bayer has agreed to make payments totaling $15,000,000.00 to settle Plaintiffs' claims, including attorneys' fees and costs.  For more details, write to the address or visit the website identified below.

ARE YOU AFFECTED?
If you purchased either of the listed Combination Aspirin Products in the U.S. for personal, family or household uses within the specific time stated, then you are a member of a Settlement Class. Be sure to visit the website for complete Class Member definitions.

WHAT ARE MY LEGAL RIGHTS?
You have a choice of whether to stay in any Settlement Class or not, and you must decide soon – the deadline for exclusion is December 20, 2012.

Stay In: you will be legally bound by the terms of the settlement, and you won't be able to sue Bayer—as part of any other lawsuit—for any claims arising from or related to the Combination Aspirin Products except for any personal injury claims. To receive benefits from the settlement, you must submit a valid, sworn Claim Form. The Claim Form must be postmarked or submitted online by April 29, 2013. Any member of any Settlement Class that does not timely submit a valid, sworn Claim Form will not be entitled to settlement benefits.

To file a Claim Form, visit www.BayerCombinationAspirinSettlement.com.

Get Out: If you get out, you will not receive benefits from the proposed settlement, but you will keep rights to sue Bayer for these claims, and will not be bound by the terms of the settlement. To be excluded from the Settlement Class, you must act before December 20, 2012. If you wish to be excluded from one or more of the Settlement Classes visit www.BayerCombinationAspirinSettlement.com.

Object: If you stay in any Settlement Class, you can object to the Settlement and must act by February 5, 2013.

WHO REPRESENTS ME?
The Court has appointed Hagens Berman Sobol Shapiro LLP and Douglas & London P.C. to represent the Settlement Classes. You may hire your own attorney, if you wish, at your own expense.

THE PROPOSED SETTLEMENT
The Court will hold a Fairness Hearing on Wednesday, March 13, 2013 at 10:00 a.m. Eastern, to determine whether the proposed settlement is fair, reasonable, and adequate and to approve attorney fees and costs. The Hearing will be at the U.S. District Court for the Eastern District of New York, 225 Cadman Plaza East, Brooklyn, New York 11201. If you are a member of a Settlement Class who did not seek to be excluded, you may write to the Court to object to the proposed settlement, and you may ask to speak at the hearing about the fairness of the proposed settlement.

HOW CAN I GET MORE INFORMATION?
If you have questions, visit www.BayerCombinationAspirinSettlement.com, call 1-877-257-5766, or write to Bayer Combination Aspirin Litigation Settlement, c/o Gilardi & Co. LLC, P.O. Box 808061, Petaluma, CA 94975-8061.


'/>"/>
SOURCE Hagens Berman Sobol Shapiro LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Champions Oncology to Present at Rodman & Renshaw Conference
2. Frost & Sullivan: Where Will Laboratory Budgets be Allocated?
3. Frost & Sullivan Acknowledges the Value Dell Healthcare and Life Sciences Brings to the Enterprise Imaging Informatics Marketplace
4. Faruqi & Faruqi, LLP is Investigating AmerisourceBergen Corporation on Behalf of its Shareholders
5. Gerald E. Quirk Joins Choate, Hall & Stewart LLP as Co-Chair of Life Sciences Group
6. Innophos To Present At 2012 KeyBanc Capital Markets Basic Materials & Packaging Conference
7. Healthy Vision & Contact Lenses - New Educational Resource Offers Important Advice On Safe Wear And Care Of Contact Lenses
8. VirtualScopics to Present at the Upcoming Rodman & Renshaw Annual Global Investment Conference
9. Novelos Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference on September 11
10. Echo Therapeutics to Present at the Rodman & Renshaw Annual Global Investment Conference
11. Varying Technology and Application Trends Pep up the Mature Research Antibodies Market, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... study highlights the necessity of health literacy within the technology advancement of diagnostic imaging. According ... , a majority of oncology patients undergo imaging screenings without understanding the nuanced risks ... ... ... Medical Diagnostic Imaging Ampronix ...
(Date:5/27/2016)... May 27, 2016 According to ... hypertension is driving ambulatory blood pressure monitoring system market ... and their ability to respond to different pressure rates, ... can lead to various cardiovascular disorders such as heart ... These diseases are growing in prevalence each year. WHO ...
(Date:5/27/2016)... 27, 2016 Kitov ... focused on late-stage drug development, today announced the ... of pivotal batches required for registration of KIT-302 ... This follows Kitov,s announcement in December ... met its primary efficacy endpoint. "We ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... 31, 2016 , ... Throughout the day, adults often find themselves reaching for a cup of ... they could be reaching for instead is a cup of Matcha green tea. Matcha is ... This sacred tea is harvested from early June to mid-July, when the leaves are the ...
(Date:5/31/2016)... ... May 31, 2016 , ... Presence Technology ... has been included by Gartner, Inc. in the Contact Center Infrastructure Magic Quadrant ... Center Infrastructure technologies, some of which include: Computer-telephony integration (CTI)/Web services interfaces, ...
(Date:5/31/2016)... ... 31, 2016 , ... St. Joseph Medical Center (SJMC) announced ... which enables physicians at SJMC’s two hospital campuses, downtown and in the Heights, ... the exchange. SJMC’s membership in the health information exchange underscores the hospital’s commitment ...
(Date:5/31/2016)... ... 31, 2016 , ... The University of Tennessee Medical Center ... the latest in Clinical Patient Pod (CPP) technologies provided through Jvion’s ... into the clinical workflow. These insights are empowering the more than 30 case ...
(Date:5/31/2016)... Prairie, MN (PRWEB) , ... May 31, 2016 , ... ... from the American Association for Laboratory Accreditation (A2LA) to include ISO 594-1 and ISO ... most common means of achieving a leak-free connection between two medical devices (e.g. a ...
Breaking Medicine News(10 mins):